Thrombosis research · 2026
Identification of new molecular mechanisms of antithrombin deficiency: six new SERPINC1 variants in a Polish cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ochotnicka Joanna, Rupa-Matysek Joanna, Klajmon Adrianna, de la Morena-Barrio María Eugenia, de la Morena-Barrio Belén, Corral Javier, Undas Anetta, Wypasek Ewa
Аннотация
INTRODUCTION: Inherited antithrombin (AT) deficiency, mainly caused by variants in the SERPINC1 gene, is a high-risk inherited thrombophilia.
OBJECTIVES: We sought to characterize the molecular mechanisms underlying AT deficiency in a series of Polish patients including long-term follow-up data.
PATIENTS AND METHODS: Twenty-nine unrelated probands (13 women [44.8%], mean [SD] age, 44.2 [13.0] years) with type I AT deficiency (n = 21, 72.4%) and type II AT deficiency (n = 8, 27.6%) who mostly had prior venous thromboembolism (n = 21, 72.4%) were screened for mutations using next-generation sequencing (NGS), long-read whole-genome sequencing or multiplex ligation-dependent probe amplification (MLPA). Hypoglycosylation was evaluated by Western blot and HPLC.
RESULTS: NGS sequencing and MLPA of SERPINC1 detected variants in 22 probands (75.9%): 13 missense (44.8%, including a new AT Kraków III: c.457T>C); 6 small deletions/insertions (20.7%, including 2 new: AT Ostrowiec: c.962dup and AT Poznań: c.[400_401insG;402_403del;406_408 + 1del]), 2 nonsense (6.9%, one new: AT Tychy: c.81G>A) and one new deletion covering exons 1 and 2 (AT Częstochowa). The nanopore sequencing revealed a new insertion of 2940 bp (a SINE-VNTR-Alu element) in intron 3 of SERPINC1 (AT Tkaczew). Congenital disorders of glycosylation were detected in two patients (7%) without any other variants. During a median follow-up of 27 (12-39) months, 21 (72.4%) patients with prior VTE receiving oral anticoagulants and no thrombotic events were recorded.
CONCLUSION: Our findings indicate the need for advanced genomic analyses to detect complex structural variants in subjects with AT deficiency including retrotransposon insertions and intronic variants.
OBJECTIVES: We sought to characterize the molecular mechanisms underlying AT deficiency in a series of Polish patients including long-term follow-up data.
PATIENTS AND METHODS: Twenty-nine unrelated probands (13 women [44.8%], mean [SD] age, 44.2 [13.0] years) with type I AT deficiency (n = 21, 72.4%) and type II AT deficiency (n = 8, 27.6%) who mostly had prior venous thromboembolism (n = 21, 72.4%) were screened for mutations using next-generation sequencing (NGS), long-read whole-genome sequencing or multiplex ligation-dependent probe amplification (MLPA). Hypoglycosylation was evaluated by Western blot and HPLC.
RESULTS: NGS sequencing and MLPA of SERPINC1 detected variants in 22 probands (75.9%): 13 missense (44.8%, including a new AT Kraków III: c.457T>C); 6 small deletions/insertions (20.7%, including 2 new: AT Ostrowiec: c.962dup and AT Poznań: c.[400_401insG;402_403del;406_408 + 1del]), 2 nonsense (6.9%, one new: AT Tychy: c.81G>A) and one new deletion covering exons 1 and 2 (AT Częstochowa). The nanopore sequencing revealed a new insertion of 2940 bp (a SINE-VNTR-Alu element) in intron 3 of SERPINC1 (AT Tkaczew). Congenital disorders of glycosylation were detected in two patients (7%) without any other variants. During a median follow-up of 27 (12-39) months, 21 (72.4%) patients with prior VTE receiving oral anticoagulants and no thrombotic events were recorded.
CONCLUSION: Our findings indicate the need for advanced genomic analyses to detect complex structural variants in subjects with AT deficiency including retrotransposon insertions and intronic variants.